Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever

Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bact...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Gill Hartley, Isobel H. Norville, Mark I. Richards, Kay B. Barnes, Kevin R. Bewley, Julia Vipond, Emma Rayner, Andreas Vente, Stuart J. Armstrong, Sarah V. Harding
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	Coxiella antibiotics bacterial counts splenomegaly PCR Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/f4f2e56b2dbc445d90035502bac07138
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f4f2e56b2dbc445d90035502bac07138
record_format	dspace
spelling	oai:doaj.org-article:f4f2e56b2dbc445d90035502bac071382021-12-01T20:08:42ZFinafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever1664-302X10.3389/fmicb.2021.760698https://doaj.org/article/f4f2e56b2dbc445d90035502bac071382021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmicb.2021.760698/fullhttps://doaj.org/toc/1664-302XFinafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bacterium which resides and replicates in acidic intracellular parasitic vacuoles. The efficacy of finafloxacin was evaluated in vivo using the A/J mouse model of inhalational Q fever and was compared to doxycycline, the standard treatment for this infection and ciprofloxacin, a comparator fluoroquinolone. Finafloxacin reduced the severity of the clinical signs of infection and weight loss associated with Q fever, but did not reduce the level of bacterial colonization in tissues compared to doxycycline or ciprofloxacin. However, histopathological analysis suggested that treatment with finafloxacin reduced tissue damage associated with C. burnetii infection. In addition, we report for the first time, the use of viable counts on axenic media to evaluate antibiotic efficacy in vivo.M. Gill HartleyIsobel H. NorvilleIsobel H. NorvilleMark I. RichardsKay B. BarnesKevin R. BewleyJulia VipondEmma RaynerAndreas VenteStuart J. ArmstrongSarah V. HardingFrontiers Media S.A.articleCoxiellaantibioticsbacterial countssplenomegalyPCRMicrobiologyQR1-502ENFrontiers in Microbiology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Coxiella antibiotics bacterial counts splenomegaly PCR Microbiology QR1-502
spellingShingle	Coxiella antibiotics bacterial counts splenomegaly PCR Microbiology QR1-502 M. Gill Hartley Isobel H. Norville Isobel H. Norville Mark I. Richards Kay B. Barnes Kevin R. Bewley Julia Vipond Emma Rayner Andreas Vente Stuart J. Armstrong Sarah V. Harding Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
description	Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bacterium which resides and replicates in acidic intracellular parasitic vacuoles. The efficacy of finafloxacin was evaluated in vivo using the A/J mouse model of inhalational Q fever and was compared to doxycycline, the standard treatment for this infection and ciprofloxacin, a comparator fluoroquinolone. Finafloxacin reduced the severity of the clinical signs of infection and weight loss associated with Q fever, but did not reduce the level of bacterial colonization in tissues compared to doxycycline or ciprofloxacin. However, histopathological analysis suggested that treatment with finafloxacin reduced tissue damage associated with C. burnetii infection. In addition, we report for the first time, the use of viable counts on axenic media to evaluate antibiotic efficacy in vivo.
format	article
author	M. Gill Hartley Isobel H. Norville Isobel H. Norville Mark I. Richards Kay B. Barnes Kevin R. Bewley Julia Vipond Emma Rayner Andreas Vente Stuart J. Armstrong Sarah V. Harding
author_facet	M. Gill Hartley Isobel H. Norville Isobel H. Norville Mark I. Richards Kay B. Barnes Kevin R. Bewley Julia Vipond Emma Rayner Andreas Vente Stuart J. Armstrong Sarah V. Harding
author_sort	M. Gill Hartley
title	Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_short	Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_full	Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_fullStr	Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_full_unstemmed	Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_sort	finafloxacin, a novel fluoroquinolone, reduces the clinical signs of infection and pathology in a mouse model of q fever
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/f4f2e56b2dbc445d90035502bac07138
work_keys_str_mv	AT mgillhartley finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT isobelhnorville finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT isobelhnorville finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT markirichards finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT kaybbarnes finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT kevinrbewley finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT juliavipond finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT emmarayner finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT andreasvente finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT stuartjarmstrong finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever AT sarahvharding finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
_version_	1718404610619604992

Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever

Ejemplares similares